Capan-2, or indeed even other desmoplastic carcinomas, may therefore propagate a distinct ECM structure that enhances the αVβ6-dependent latent TGF-β activation pathway [40] thereby requiring a prolonged treatment period with repeated injection of 3G9 IgG. The gene discussed is TGFB1; the disease is carcinoma.